Global Leader in Medical Technology Offers for Sale Seven Patent Portfolios Through ICAP Patent Brokerage

CHICAGO, Oct. 19, 2011 /PRNewswire/ -- ICAP Patent Brokerage, a division of ICAP plc, the world's largest intellectual property brokerage and patent auction firm, is offering for sale seven patent portfolios from a major medical device company. The available portfolios disclose patented technology related to biomaterials, bio-prosthetics, device failure control, high-intensity focused ultrasound (HIFU) energy, improved blood management, medical devices and suction ablation.

(Logo:  http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)

Portfolios Available for Sale:

Biomaterials for Stable Medical Implantable Devices

This portfolio discloses medical devices constructed using biomaterial compounds or biostable polymers such as polyurethanes. Free of ester, ether, and carbonate linkages, the hard or soft segments of the polymers include moieties which reduce susceptibility to both oxidation and hydrolysis.

Bio-Prosthetic Devices & Methods

This portfolio discloses methods for manufacturing materials such as cross-linked collagen-based materials for bio-prosthetic devices, including implants. The technology affords control over the flexibility and stiffness of resulting materials.

Failure Control with Selective Protection of Electronic Components

This portfolio discloses techniques for protecting various electronic components of a device. In the event of device failure, the non-critical components stop the operation of critical components, mitigating damage to the system and/or user.

High Intensity Focused Ultrasound Energy for Ablation

This portfolio discloses devices and techniques for utilizing HIFU energy for localized, controlled tissue ablation. In particular, the disclosed devices can be used to form a customized lesion, or a lesion comprising disconnected lesion segments, applicable to the treatment of multiple diseases.  

Improved Blood Management Techniques

This portfolio discloses devices and techniques for the management of hemostasis. The technology rapidly determines heparin levels in blood or other fluids such as plasma, as well as quantitatively assessing the coagulation process.

Medical Devices & Techniques for Joining Hollow Bodies

This portfolio discloses medical devices and techniques for treating a patient with an anastomosis procedure or other techniques resulting in the joining of two bodies without a suture. In particular, the technology describes securing two hollow bodies using either magnetic or mechanical components.

Suction Ablation Devices & Techniques

This portfolio discloses a medical ablation device that uses a vacuum or suction force in conjunction with ablation element(s) to create lesions in tissue. The suction affords a robust relationship between the ablating element and tissue. This technology is particularly suitable for use with difficult to ablate tissue including tissue that can be expected to move during the ablation process.

"These portfolios feature superlative medical technology developed and refined over the course of decades. They warrant close attention," said Cameron Gray, SVP at ICAP Patent Brokerage.

To learn more about the assets available for license in this portfolio:

Contact Cameron Gray of ICAP Patent Brokerage at (650) 421-3089 or [email protected]

About ICAP Patent Brokerage

ICAP Patent Brokerage is a division of ICAP plc and the world's largest intellectual property brokerage and patent auction firm.

About ICAP

ICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to www.icap.com.

SOURCE ICAP Patent Brokerage

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED